Cargando…
Teicoplanin: an alternative drug for the treatment of COVID-19?
In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient...
Autores principales: | Baron, Sophie Alexandra, Devaux, Christian, Colson, Philippe, Raoult, Didier, Rolain, Jean-Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102624/ https://www.ncbi.nlm.nih.gov/pubmed/32179150 http://dx.doi.org/10.1016/j.ijantimicag.2020.105944 |
Ejemplares similares
-
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
por: Devaux, Christian A., et al.
Publicado: (2020) -
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
por: Colson, Philippe, et al.
Publicado: (2020) -
Arbekacin as an Alternative Drug to Teicoplanin for the Treatment of MRSA Infection
por: Hwang, Ji-Hee, et al.
Publicado: (2016) -
ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
por: Devaux, Christian A., et al.
Publicado: (2020) -
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
por: Colson, Philippe, et al.
Publicado: (2020)